Senior Analyst, SEC Reporting & Technical Accounting
- Market p25–p75
- $135k–$198k
- BridgeBio Pharma p25–p75
- $145k–$170kn=3
- Opened · 30d
- +2
- Closed · 30d
- −3
- Opened · 7d
- +1,3695% of open
- All other
- 625,139open
Mavericks Wanted
When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible.
Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.
About the job
Mavericks Wanted
When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on
In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare disease, and develop life-changing medicines for patients with unmet needs as fast as humanly possible.
Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll ask "why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical & thoughtful use of AI to improve clarity, speed, and quality of work.
Who You Are
The Senior Analyst, SEC Reporting & Technical Accounting is a key hands-on contributor to our growing accounting team, responsible for preparing and coordinating on deliverables for the Company's quarterly and annual reporting cycle. This position will play a key role in bridging activities from accounting operations to external reporting with direct involvement in recording journal entries, preparing reconciliations, concluding on judgmental technical accounting matters, and drafting and tying out portions of the Company’s 10-Q, 10-K, and earnings release. The position reports to the Senior Accounting Manager, SEC Reporting & Technical Accounting and requires close collaboration with internal business partners.
A successful candidate thrives in a fast-paced, high-growth environment and is proactive, highly organized, results-oriented, and analytical, with strong attention to detail and excellent communication skills. This individual exercises sound judgment, takes ownership of outcomes, and is highly motivated to consistently deliver high-quality results while supporting the growth and scalability of the organization.
Responsibilities
- Prepare the quarterly and annual SEC filings (10-Q, 10-K, and earnings release), including select financial statements, footnote disclosures, and supporting schedules.
- Assist with technical accounting research and prepare position memo on complex or non-routine accounting matters
- Support a variety of complex accounting areas. Prior expertise in all areas is not required. The role requires only a desire and aptitude to develop deep technical expertise. These areas include leases (ASC 842), equity method accounting (ASC 323), debt and deferred royalty obligations (ASC 470), preferred stock and other complex equity instruments, embedded derivatives (ASC 815), earnings per share (ASC 260), noncontrolling interests (ASC 810), contingencies (ASC 450), and related party disclosures (ASC 850).